TY - JOUR
T1 - A phase i dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
AU - Raez, Luis E.
AU - Papadopoulos, Kyriakos
AU - Ricart, Alejandro D.
AU - Chiorean, E. Gabriella
AU - Dipaola, Robert S.
AU - Stein, Mark N.
AU - Rocha Lima, Caio M.
AU - Schlesselman, James J.
AU - Tolba, Khaled
AU - Langmuir, Virginia K.
AU - Kroll, Stewart
AU - Jung, Donald T.
AU - Kurtoglu, Metin
AU - Rosenblatt, Joseph
AU - Lampidis, Theodore J.
N1 - Funding Information:
Acknowledgments We thank the patients who participated in this trial and the study coordinators, nurses, clinical research assistants and doctors who assisted with the research. This research is supported by Threshold Pharmaceuticals Inc.
PY - 2013/2
Y1 - 2013/2
N2 - Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods: A modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m2 for 3 of every 4 weeks beginning on day 1 of week 2. Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-week cycle for up to 12 cycles. Results: Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule. There were no dose-limiting toxicities which met the MTD criteria. The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration. Therefore, 63 mg/kg was selected as the clinically tolerable dose. The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %). Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response. There was no PK interaction between 2DG and docetaxel. Conclusion: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.
AB - Purpose: This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. Methods: A modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m2 for 3 of every 4 weeks beginning on day 1 of week 2. Following the completion of dose escalation, cohorts of patients were then treated with 2DG for 21 days or every day of each 4-week cycle for up to 12 cycles. Results: Thirty-four patients were enrolled: 21 on every other week, 6 on a 21 of 28-day cycle and 7 on the continuous 2DG dosing schedule. There were no dose-limiting toxicities which met the MTD criteria. The most common adverse events were fatigue, sweating, dizziness and nausea mimicking the hypoglycemic symptoms expected from 2DG administration. Therefore, 63 mg/kg was selected as the clinically tolerable dose. The most significant adverse effects noted at 63-88 mg/kg doses were reversible hyperglycemia (100 %), gastrointestinal bleeding (6 %) and reversible grade 3 QTc prolongation (22 %). Eleven patients (32 %) had stable disease, 1 patient (3 %) partial response and 22 patients (66 %) progressive disease as their best response. There was no PK interaction between 2DG and docetaxel. Conclusion: The recommended dose of 2DG in combination with weekly docetaxel is 63 mg/kg/day with tolerable adverse effects.
KW - 2-Deoxy-d-Glucose
KW - Breast cancer
KW - Docetaxel
KW - Head and neck cancers
KW - Lung cancer
KW - Phase I
UR - http://www.scopus.com/inward/record.url?scp=84874116164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874116164&partnerID=8YFLogxK
U2 - 10.1007/s00280-012-2045-1
DO - 10.1007/s00280-012-2045-1
M3 - Article
C2 - 23228990
AN - SCOPUS:84874116164
SN - 0344-5704
VL - 71
SP - 523
EP - 530
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 2
ER -